Physiologically Based Pharmacokinetic Modeling of Nilotinib for Drug‐Drug Interactions, Pediatric Patients, and Pregnancy and Lactation
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.2379 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Xiaomei I Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA. Hauptthemen laut MEDLINE: Lactation, Models, Biological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: US Food and Drug Administration, Perinatal Health Center of Excellence.
Themen: Stillen
Abstract (Originalsprache)
Nilotinib is a second‐generation BCR‐ABL tyrosine kinase inhibitor for the treatment of Philadelphia chromosome‐positive chronic myeloid leukemia in both adult and pediatric patients. The pharmacokinetics (PK) of nilotinib in specific populations such as pregnant and lactating people remain poorly understood. Therefore, the objectives of the current study were to develop a physiologically based pharmacokinetic (PBPK) model to predict nilotinib PK in virtual drug‐drug interaction (DDI) studies, as well as in pediatric, pregnant, and lactating populations. The nilotinib PBPK model was built in PK‐Sim, which is part of the free and open‐source software Open Systems Pharmacology. The observed clinical data for the validation of the nilotinib models were obtained from the literature. The model reasonably predicted nilotinib concentrations in the adult population; the DDIs between nilotinib and rifampin or ketoconazole in the adult population; and the PK in the pediatric, pregnant, and lactating populations, although in the latter 2 populations plasma concentrations were slightly underestimated. The ratio of predicted versus observed PK parameters for the adult model ranged from 0.71 to 1.11 for area under the concentration‐time curve and 0.55 to 0.95 for maximum concentration. For the DDI, the predicted area under the concentration‐time curve ratio and maximum concentration ratio fell within the Guest criterion. The current study demonstrated the utility of using PBPK modeling to understand the mechanistic basis of PK differences between adults and specific populations, such as pediatrics, and pregnant and lactating individuals, indicating that this technology can potentially inform or optimize dosing conditions in specific populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA.
- Office of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, MD, USA.
- Bayer HealthCare SAS, Loos, France, on behalf of: Pharmacometrics/Modeling and Simulation, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
ORCID-Profile: Gilbert J Burckart, André Dallmann
Förderung
- US Food and Drug Administration
- Perinatal Health Center of Excellence
Zitieren
APA
Liu, X. I., Leong, R., Burckart, G. J., & Dallmann, A. (2024). Physiologically Based Pharmacokinetic Modeling of Nilotinib for Drug‐Drug Interactions, Pediatric Patients, and Pregnancy and Lactation. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2379
Vancouver
Liu XI, Leong R, Burckart GJ, Dallmann A. Physiologically Based Pharmacokinetic Modeling of Nilotinib for Drug‐Drug Interactions, Pediatric Patients, and Pregnancy and Lactation. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2379
BibTeX
@article{Liu2024,
author = {Liu, Xiaomei I and Leong, Ruby and Burckart, Gilbert J and Dallmann, André},
title = {Physiologically Based Pharmacokinetic Modeling of Nilotinib for Drug‐Drug Interactions, Pediatric Patients, and Pregnancy and Lactation},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.2379}
}
EUVIMED